Cargando…
Retraction Note to: Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway
Autores principales: | Huang, Han-Ming, Huang, Xiao-Yu, Wu, Shao-Ping, Chen, Can-Keng, He, Xin-Hua, Zhang, Yong-Fa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380287/ https://www.ncbi.nlm.nih.gov/pubmed/35971067 http://dx.doi.org/10.1186/s11658-022-00369-x |
Ejemplares similares
-
Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway
por: Huang, Han-Ming, et al.
Publicado: (2022) -
Retraction Note: Down-regulation of kappa opioid receptor promotes ESCC proliferation, invasion and metastasis via the PDK1-AKT signaling pathway
por: Huang, Han-Ming, et al.
Publicado: (2023) -
Retraction Note: Inhibited MicroRNA-301 Restrains Angiogenesis and Cell Growth in Esophageal Squamous Cell Carcinoma by Elevating PTEN
por: Wang, Bin, et al.
Publicado: (2023) -
Retraction Note: Ferroportin in the progression and prognosis of hepatocellular carcinoma
por: Wang, Qin, et al.
Publicado: (2015) -
Retracted: CaMKK2 Promotes the Progression of Ovarian Carcinoma through the PI3K/PDK1/Akt Axis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)